Latest Ai Platforms News

Artrya Limited has successfully completed a strongly supported Share Purchase Plan, raising approximately A$5 million despite significant oversubscription. This follows a recent $75 million placement, underscoring investor confidence in its AI-driven coronary artery disease platform.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

dorsaVi has achieved a major engineering milestone by validating its RRAM-powered Reflex Platform, delivering neural reflex decisions in under one microsecond with ultra-low energy consumption. This breakthrough paves the way for next-generation robotics, prosthetics, and wearable devices that require rapid, energy-efficient reflex actions.

InteliCare Holdings has raised $2 million through a two-tranche placement to accelerate its AI-driven aged care platform and terminated a convertible note facility to streamline its capital base.

Artrya Limited has raised A$75 million through a two-tranche placement and launched a A$5 million share purchase plan to fast-track the U.S. commercialisation of its AI-powered Salix platform following FDA clearance.

SenSen Networks has secured $2 million in new contracts across Singapore, the USA, and Australia, reinforcing its position as a leader in Live Awareness AI solutions. The company also strengthened its balance sheet with $1.5 million cash received from a recent Montreal project.

SenSen Networks has reported a strong financial turnaround in FY2025, driven by rapid expansion in North America and innovative AI kerb enforcement technology. The company’s improved margins and positive cash flow signal a promising outlook for its Smart Cities strategy.

SenSen Networks has reported a strong financial turnaround for the year ended June 2025, posting a 26.5% increase in revenue alongside a return to profitability after previous losses.

Hiremii Limited reported a near-flat revenue for FY2025 with a 25% increase in net loss, while pushing forward its AI-driven recruitment platform and completing a key acquisition to expand market reach.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

MONEYME Limited reported a robust FY25 with a 28% increase in its loan book to $1.6 billion and a positive operating cash profit of $24 million, underpinned by improved credit quality and strategic funding initiatives.